Truffle Differentiation
Truffle Capital screens proprietary technologies and products in large European technology companies that present strong market potential but lack corporate support.
We estimate that the top 100 technology-driven European companies waste about 15% to 20% of their R&D expenditures on projects that are not properly exploited when they fall outside of corporate priorities. And we believe there is a great need for private equity funding for these projects.
In many cases, we have approached management to suggest they consider selling a non-strategic asset. We have completed spin-offs from major groups including Areva, Abbott Diagnostic, Edap Technomed, Infineon, Inserm, Knaug, Société Générale, and Schneider.
Spin-off companies are an attractive investment target since they combine the advantages of a late-stage technology or product with a low risk profile and low valuation at entry. This should result in faster returns on investment